Valproate Class Action Suit, EMA report

Sodium valproate, a common antiepileptic drug that has been in use since 1967 has been the subject of separate class action suits against the French manufacturer Sanofi because of claims that the company and regulators knew of its teratogenic effect for 40 years but didn’t pass on warnings to patients. The European Medicines Agency (EMA) has recently published a report of a public hearing on the matter.

Read the report here →